Zepbound (tirzepatide 5-15 mg) — FDA-approved November 2023 for chronic weight management. −22.5% body weight at 72 weeks (SURMOUNT-1). $349-499/mo via LillyDirect self-pay.
GIP/GLP-1 dual receptor agonist
Generic name: tirzepatide · Eli Lilly
Updated May 24, 2026
Affiliate disclosure: we earn commission on signups via partner provider links. Editorial ranking stays independent.
Top 3 providers prescribing Zepbound
See full ranking →What the trial showed
In the SURMOUNT-1 (phase 3, obesity) trial, −20.9% mean body-weight reduction at 15 mg over 72 weeks.
Zepbound is a GIP/GLP-1 dual receptor agonist used for Chronic weight management and Obstructive sleep apnea (adults with obesity).
Slows digestion
Food sits in the stomach longer, so smaller portions feel full
Reduces appetite signals
Brain receptors quiet the food-reward loop — what patients call lower "food noise"
Improves blood-sugar control
Stimulates insulin after meals; lowers glucagon production
List price
$1086
/month, cash, no insurance
SURMOUNT-1 (phase 3, obesity)
−20.9%
mean body-weight reduction at 15 mg over 72 weeks
Form
Weekly injection
subcutaneous
FDA approved
2023
for chronic weight management
Affiliate links — we earn commission on conversions; editorial ranking is independent.
Source: SURMOUNT-1 (phase 3, obesity) pivotal trial
Mechanism of action
Last Revised — by Dr. Jane Novak, MD, MPH
Source: Tirzepatide Once Weekly for the Treatment of Obesity — NEJM, 2022
Weight-loss trajectory · SURMOUNT-1 (15 mg arm)
Mean change in body weight over the 72-week trial.
Editorial grades summarizing study quality and convergence. How we grade.
| Claim | Grade | Basis |
|---|---|---|
~20.9% mean body-weight reduction at 15 mg over 72 weeks Source: NEJM, 2022 (opens in a new tab) SURMOUNT-1 RCT (n=2,539); class-leading effect size to date | AStrong evidence | SURMOUNT-1 RCT (n=2,539); class-leading effect size to date |
Maintained weight loss requires continued use Source: JAMA, 2023 (opens in a new tab) SURMOUNT-4 withdrawal trial: 14% regain within 36 weeks of stopping | AStrong evidence | SURMOUNT-4 withdrawal trial: 14% regain within 36 weeks of stopping |
Improves obstructive sleep apnea (AHI) in adults with obesity Source: NEJM, 2024 (opens in a new tab) SURMOUNT-OSA 1 + 2; FDA approved indication added in 2024 | AStrong evidence | SURMOUNT-OSA 1 + 2; FDA approved indication added in 2024 |
Improves cardiovascular outcomes in adults with obesity (no diabetes) SURMOUNT-MMO ongoing; class-level signal extrapolated from Wegovy SELECT | CLimited evidence | SURMOUNT-MMO ongoing; class-level signal extrapolated from Wegovy SELECT |
Causes long-term medullary thyroid cancer in humans Source: accessdata.fda.gov (opens in a new tab) Rodent-only signal; no human cases attributed to GLP-1/GIP agonists | FNo evidence | Rodent-only signal; no human cases attributed to GLP-1/GIP agonists |
Same molecule as Mounjaro, weight-management indication. Step every 4 weeks; three valid maintenance doses.
Weeks 1–4
2.5 mg
Starter — tolerance building
Weeks 5–8
5 mg
First therapeutic step
Weeks 9–12
7.5 mg
Optional step
Weeks 13–16
10 mg
Common maintenance
Weeks 17–20
12.5 mg
Optional step
Weeks 21–72
15 mg
Highest-efficacy maintenance
Target doseSource: Zepbound prescribing information (opens in a new tab)
FDA approval
2023
Weight + OSA (2024)
Max dose
15 mg
Weekly injection
Avg loss
20.9%
72 wks (SURMOUNT-1)
List price
$1,059
/month cash
Monthly cost in the US
Real out-of-pocket varies. Cash list price is what the pharmacy bills without insurance. Commercial copay assumes a tier-3 specialty plan. Savings-card numbers come from manufacturer programs.
$1,059.87/mo
What you pay at the pharmacy with no insurance, no coupons.
$25–$250/mo
Typical tier-3 specialty copay if your plan covers GLP-1s for your indication. Coverage is uneven.
$1,059.87$25–$25/mo
Commercially insured covered — $25/mo. Uninsured: up to $463/mo off, max $1,800/yr. Not for Medicare/Medicaid.
Prices verified against manufacturer pages and FDB pharmacy data. Last reviewed: 2026. Affordability programs change; verify eligibility directly with the manufacturer before assuming you qualify.
Pick your plan tier + deductible status for a tier-average estimate. Tap to expand.
Patient-reported outcomes from the SURMOUNT-1 PRO substudy substudy, plus the Drugs.com community satisfaction rating. These are aggregate signals, not individual testimonials.
Treatment satisfaction
+12.4
IWQOL-Lite-CT total score improvement vs placebo at week 72
Lost ≥20% weight
57%
Share of 15 mg participants reaching the ≥20% threshold
Lost ≥25% weight
36%
15 mg arm — class-leading depth of response
Stayed on therapy at 1yr
~84%
Trial retention; real-world adherence is lower
Drugs.com community rating from 462 verified user reviews. View on Drugs.com → (opens in a new tab)
Source: SURMOUNT-1 PRO substudy (Lilly press release Oct 2024) + Drugs.com community rating accessed 2026.
Check Zepbound against another medication
Type a medication you currently take. We'll route you to the full interaction report — and you should still confirm with your prescriber before changing anything.
Powered by FDA prescribing information cross-references. Not medical advice — for anything serious, call your prescriber or 911.
Supply normal · as of 2026-05-01
This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.
Zepbound is FDA-approved to treat:
FDA-label titration timeline for Zepbound. Doses ramp gradually to limit gastrointestinal side effects; never accelerate the schedule without prescriber input.
Step 1
Weeks 1–4
2.5 mg
Step 2
Weeks 5–8
5 mg
Step 3
Weeks 9–12
7.5 mg
Step 4
Weeks 13–16
10 mg
Step 5
Week 17+
15 mg
Maintenance
Source: FDA prescribing information. Weekly subcutaneous injection. Dose escalation may be delayed if side effects are intolerable. Doses listed here are typical; your prescriber may adjust based on tolerance and response.
Titration schedule
Each escalation holds 4 weeks before the next step up — standard pattern across GLP-1 weight-management labels.
Body-weight outcomes from the pivotal trials that anchor FDA approval. Each chart plots the active arm against the placebo or head-to-head comparator, week by week.
SURMOUNT-1
Percentage change in body weight from baseline to week 72
Key takeaways
Incidence rates for Zepbound from the FDA prescribing information and pivotal trials. Numbers are active arm vs. placebo — the gap tells you how much of an effect is drug-caused vs. background.
Excess vs placebo: +20.1 pp
Excess vs placebo: +15.7 pp
"Excess vs placebo" is the percentage-point difference between active treatment and placebo arms. A small excess (e.g., headache at +2.6 pp) suggests the side effect is mostly background noise, not drug-caused. A large excess (e.g., nausea at +28 pp) is a strong drug signal.
Sources
Trial percentages are population averages. Your individual experience may differ. Severity labels reflect typical clinical impact, not how it will feel for any specific patient.
Pregnancy
C — Discontinue at least 1 month before a planned pregnancy.
Breastfeeding
Not recommended while breastfeeding.
Missed dose
If within 4 days: take as soon as remembered. If more than 4 days: skip and resume normal schedule.
Storage
Refrigerate before first use. After first use, room temperature up to 21 days.
What Zepbound costs in 2026
From $349/mo via telehealth68% off retail
Average retail in the US: $1086/month. We compare 4 pricing paths below so you can see exactly where the savings come from.
| Pricing path | Monthly cost |
|---|---|
Retail pharmacy Cash, no insurance, no coupon | $1,086 |
GoodRx coupon Same pharmacy, public coupon | $1,059 |
Commercial insurance Typical copay (median) | $25 |
Ro Cheapest editorially-vetted path | $349 68% off retail |
RxNorm Code: 2683551
Verified user experiences with Zepbound. Reviews are moderated before publishing.
All clinical claims on this page are sourced from the FDA prescribing information and peer-reviewed literature. Verify the most current label before clinical decisions.
See our data sources of truth and the consolidated references bibliography for every claim cited above.
Week 1-4
Sub-therapeutic for weight loss — exists to build GI tolerance. Mild nausea common; appetite suppression noticeable in 2nd half.
Week 5-12
Weight loss accelerates each step. SURMOUNT-1 averages: ~5 kg by week 12, often without significant lifestyle change.
Week 13-20
Highest weight-loss benefit lives here. Side-effect intensity often blunts compared to early steps. Add resistance training to retain lean mass.
Week 20+
Lilly recommends the lowest dose maintaining weight loss. 15 mg is the highest-efficacy maintenance; 5 mg the gentlest.
Myth
Zepbound is not as effective as bariatric surgery.
Fact
Surgical procedures still average 25-30% body weight loss vs Zepbound 20.9%. The gap narrows materially at 15 mg and the trial endpoint is short (72 weeks); ongoing extension data may close it further.
Myth
You can switch from Ozempic to Zepbound 1:1 by mg.
Fact
Different molecules and different receptor profiles — semaglutide and tirzepatide are not interchangeable by milligram. Clinicians typically reset to the lowest Zepbound dose (2.5 mg) regardless of prior semaglutide dose.
Myth
If Zepbound caused side effects, you'll have them again on every refill.
Fact
Most GI side effects (nausea, constipation, reflux) are titration-driven and peak in weeks 1-2 of each step-up. Steady-state on maintenance is generally well tolerated.
“Zepbound's 22% average weight loss is genuinely class-leading right now, but the headline obscures variance — some patients lose 30% and others 8%. Setting expectations on the range, not just the average, is half the work of starting someone on tirzepatide.”
peaks fade
Typical 16-week titration schedule. Individual experience varies — track yours with the printable tracker.
Wk 1-2
Peak nausea — eat small protein-forward meals; hydrate.
Wk 3-4
Constipation climbs as GI motility slows. Add fiber + magnesium.
Wk 5-8
Symptoms re-spike for ~7 days after each escalation.
Wk 9-12
GI complaints meaningfully fade. Weight loss accelerates.
Wk 13-16
Hair shedding from rapid weight loss may appear (resolves by month 6).
Wk 17+
Most side effects resolved. Watch for gallbladder symptoms long-term.
Frequencies and timing aggregated from FDA prescribing information (Wegovy, Zepbound, Mounjaro, Ozempic) and the STEP/SURMOUNT trial datasets.
12-month cost tracker
Average US retail pharmacy price, per 28-day supply. Hand-curated; updated monthly.
Cash price held flat over the past year
Prices reflect average list at major US pharmacies (CVS, Walgreens, Walmart). Your actual cost depends on insurance, pharmacy choice, and savings-card eligibility.
Where to get a prescription
Ranked by our editorial team. All accept new patients, ship 50-state, and use licensed US prescribers. Pricing reflects starting monthly cost as of 2026-05.
Full primary-care telehealth with GLP-1 — the pick for patients who want ongoing PCP integration.
Save ~$9,730.44/yr vs cash list price
Marketplace pricing — book a licensed clinician directly, medication filled through their pharmacy of choice.
Save ~$12,010.44/yr vs cash list price
Weight Watchers-owned medical weight loss platform combining GLP-1s with coaching.
Sponsored partnerships. We earn commission when readers sign up. Editorial ranking is independent — full methodology at /how-we-rank.
Cash, insured, and manufacturer-discount prices across 2026. Refreshed monthly from published provider rate cards.
| Dose | Supply | Retail (FDA list)Cash, no coupons | Cash + couponGoodRx / direct-to-patient | With insuranceTypical commercial copay | Mfr savings cardEligibility required |
|---|---|---|---|---|---|
| 2.5 mg | 4-dose pen | $1086 | $349 | $25 | $25 |
| 5 mg | 4-dose pen | $1086 | $499 | $25 | $25 |
| 7.5 mg | 4-dose pen | $1086 | $499 | $25 | $25 |
| 10 mg | 4-dose pen | $1086 |
Prices are illustrative. Your specific cost depends on plan formulary, pharmacy chosen, savings-card eligibility, and current coupon programs.
Percentage of patients reporting each symptom at each week bucket. Pooled from FDA prescribing information + AERS pharmacovigilance + trial secondary endpoints. Individual experience varies.
| Symptom | Wk 1-2 | Wk 3-4 | Wk 5-8 | Wk 9-12 | Wk 13-24 | Wk 24+ |
|---|---|---|---|---|---|---|
| NauseaSURMOUNT-1 + label | 28% | 24% | 17% | 11% | 8% | 5% |
| DiarrheaSURMOUNT-1 | 22% | 19% | 14% | 10% | 7% | 5% |
2026-05-31Minor updateby Glpverdict editorial team
Added dosage price table reflecting Lilly Direct vials + sub-section reference pages.
2026-05-15Major updateby Jane Novak, MD, MPH
Evidence-graded claim table (5 claims), SURMOUNT-1 + SURMOUNT-OSA pivotal cards, dose-titration ladder.
Telehealth providers + manufacturer programs that prescribe or supply Zepbound. Editorial fit notes on each.
Insurance-friendly telehealth
Ro
Largest US weight-loss telehealth; PA + appeals support
Best for: Insurance-friendly with strong PA filing infrastructure
Affiliate
Cash-pay telehealth
Hims
Cash-pay floor; oral semaglutide from $149/mo
Best for: Cheapest sustainable cash-pay path
Affiliate
Insurance-friendly telehealth
Sequence (WeightWatchers Clinic)
WW Clinic — coaching + GLP-1 prescribing bundle
Best for: Coaching-integrated weight management
Direct
Insurance-friendly telehealth
Found
Anti-obesity meds + behavioral coaching, insurance-first
Best for: Insurance + lifestyle approach
Direct
Insurance-friendly telehealth
Calibrate
12-month program: GLP-1 + behavioral curriculum
Best for: Year-long structured program
Direct
Insurance-friendly telehealth
Form Health
Board-certified obesity medicine clinicians
Best for: Specialist obesity-medicine care
Direct
Insurance-friendly telehealth
PlushCare
50-state coverage, in-network with most major insurers
Best for: In-network insured care
Direct
Compounded 503A telehealth
Henry Meds
Compounded semaglutide + tirzepatide, cash-pay $149+
Best for: Cheapest compounded 503A access
Affiliate
Compounded 503A telehealth
Mochi Health
Compounded GLP-1 + nutritionist coaching, in-network for some plans
Best for: Compounded with nutrition coaching
Direct
Compounded 503A telehealth
Eden
Compounded semaglutide + tirzepatide, simple cash-pay
Best for: Streamlined cash-pay compounded access
Direct
Compounded 503A telehealth
FuturHealth
Compounded GLP-1 + AI-assisted personalization
Best for: AI-driven cash-pay model
Direct
Men's-focused telehealth
Hone Health
Men's-focused: GLP-1 + TRT coordination
Best for: Coordinated TRT + GLP-1 for men
Direct
LGBTQ+-affirming telehealth
Plume
Trans-led HRT + GLP-1 coordination
Best for: Trans + nonbinary affirming care
Direct
LGBTQ+-affirming telehealth
Folx Health
LGBTQ+-affirming broader primary care + weight management
Best for: LGBTQ+ primary care home for GLP-1
Direct
Manufacturer savings programs
Lilly Cares Foundation
Free Eli Lilly meds for income-qualified patients (Mounjaro, Zepbound)
Best for: Income-qualified uninsured Lilly drugs
Direct
Manufacturer savings programs
Lilly Direct
Direct-to-patient Zepbound vials from $349/mo cash
Best for: Self-pay Zepbound vials (no insurance)
Direct
Pharmacy discount platforms
GoodRx
Free pharmacy coupons; 10-30% off brand cash prices
Best for: Off-formulary backup when nothing else works
Direct
Pharmacy discount platforms
SingleCare
Pharmacy discount card; competitive with GoodRx
Best for: Alternative discount card for price comparison
Direct
Patient advocacy + education
Obesity Action Coalition
National patient advocacy organization; neutral resource directory
Best for: Education + advocacy + community
Direct
Editorial selection. "Direct" links go to the company’s homepage — we are not yet an affiliate partner with them and earn no commission on those signups. "Affiliate" links route through our /go redirect with commission tracking.
6 ways to save
Stacking two of these typically cuts more than a single savings card alone. Eligibility is program-specific; every link goes to the official source so you can verify.
Manufacturer savings card
Novo Nordisk's Wegovy Savings Offer and Lilly's Zepbound Savings Card reduce commercially-insured patients' copays. Eligibility excludes Medicare / Medicaid / Tricare. Terms and dollar amounts change quarterly — confirm on the brand site before signup.
Open program page →Verified 2026-06-01
HSA or FSA
GLP-1 medications prescribed for an IRS-qualified condition (T2D / chronic weight management with prescriber documentation) are eligible for HSA / FSA reimbursement. Use pre-tax dollars; save your invoices for substantiation.
Open tool →Verified 2026-06-01
Patient-assistance programs
Novo Nordisk PAP and Lilly Cares offer drug at no or reduced cost to qualified uninsured / underinsured patients. Income-tested; clinician submits the form. Approval windows are 30-90 days.
Open program page →Verified 2026-06-01
Medicare Extra Help (LIS)
Federal Medicare law has historically excluded weight-loss agents; 2024 CMS rulemaking is evolving. For T2D indications (Ozempic, Mounjaro, Rybelsus) Extra Help can cover most cost when the drug is on your Part D formulary. Check Medicare.gov for current status.
Open program page →Verified 2026-06-01
Tax deduction angle
Out-of-pocket prescription costs exceeding 7.5% of adjusted gross income are deductible on Schedule A. Save every receipt; pair with HSA for the strongest tax stack. Talk to a tax professional for your situation.
Open program page →Verified 2026-06-01
Cheapest cash-pay channel
Telehealth providers' cash-pay tiers (compounded routes; brand via savings card) routinely beat retail pharmacy cash. Compare current monthly cost on our ranking — prices updated monthly.
Open tool →Verified 2026-06-01
Editorial: we earn no commission on government-program signups. Cash-pay channel links use tracked /go redirects to affiliated telehealth providers — see disclosure. Savings-program terms change frequently — confirm dollar amounts and eligibility on each official page before signup. Each card shows the last date our editorial team confirmed the link.
Editorial composite — your prescriber's protocol may differ. Individual timelines vary; call your prescriber if symptoms intensify rather than ease.
Days 1-3
First injection, mild appetite shift
Most patients notice subtler hunger cues within 48-72 hours. Some experience mild nausea — eat smaller, lower-fat meals; hydrate consistently.
Days 4-7
Side effects peak then ease
Mild GI side effects (nausea, soft stool, fatigue) typically peak around day 4-5 then settle. If they intensify, contact your prescriber before stepping up.
Weeks 2-4
Steady dose, adapting body
You stay at the starter dose for 4 weeks before the first step-up. Hunger and cravings continue declining; energy normalizes for most.
Week 5+
First dose escalation
Your prescriber steps you up to the next dose tier per the FDA label. Expect a brief return of GI side effects for 3-7 days as your body re-adapts.
Month 2+
Therapeutic dose territory
By week 9 most patients reach a therapeutic dose. Visible weight change usually appears 4-6 weeks after this point. Track progress monthly; do not weigh daily.
Your prescriber may slow any step where side effects are still settling. See the FDA label for the official titration schedule for Zepbound.
What you're paying for
Editorial composite across affiliated providers. Per-provider breakdowns live on each provider page — terms vary.
Licensed clinician visit
Initial asynchronous or video consult with a clinician licensed in your state. Eligibility, dosing, and any contraindications reviewed against your intake.
Medication, shipped
Brand or compounded GLP-1 prescription dispensed by a US-licensed pharmacy and shipped temperature-controlled to your address.
Ongoing care messaging
Async clinician messaging for side-effect management, dose-step questions, and refill timing. Most providers respond within one business day.
Refills + cost adjustments
Automatic refill scheduling tied to your dose cadence; price re-priced monthly when manufacturer programs or program tiers change.
Lab work, consult re-runs, and certain tier upgrades may incur additional cost depending on provider — confirm on the provider page before signup.
Pulled from our /q-and-a corpus by topical match. Every answer is written by a licensed clinician on staff.
Wegovy vs Zepbound — which one actually loses more weight?
Head-to-head SURMOUNT-5 (NEJM 2024) put max-dose tirzepatide (Zepbound) at 20.2% mean weight loss over 72 weeks vs 13.7% for max-dose semaglutide (Wegovy) — a 6.5-point gap. Zepbound patients also hit ≥15% loss at nearly twice the rate. Trade-off: tirzepatide GI side effects are slightly higher at max dose, and supply/pricing has been less stable. For most patients starting fresh, Zepbound is the higher-efficacy pick; Wegovy remains the choice if your insurance covers it and Zepbound is not on formulary.
Full answer
Can I skip a week of my GLP-1 to make the vial last longer?
Skipping a week is not the same as extending a taper — semaglutide has a ~1-week half-life and tirzepatide is ~5 days, so a skipped week drops your steady-state level below therapeutic range and appetite rebounds sharply. If cost is the driver, the two paths that actually work are the manufacturer savings card (Wegovy/Zepbound) or switching to compounded through a telehealth provider ($99-249/mo). See /guides/lower-glp1-cost for the full menu.
Full answer
My BMI is 25 — can I get Zepbound?
Under the FDA label, no — Zepbound is approved for BMI ≥30 or ≥27 with a weight-related comorbidity, and cash-pay telehealth providers largely follow the same threshold to stay on-label. Off-label prescribing exists but is uncommon at BMI 25 and increases legal + insurance exposure for the prescriber. The realistic paths at BMI 25 are: address a specific comorbidity (sleep apnea, PCOS, MASH) if present, or focus on structured lifestyle programs — a GLP-1 at that starting weight is a high-risk-low-reward choice.
Full answer
Can I take collagen powder with Zepbound?
Yes, no known interaction. Collagen is a protein source — counts toward your daily protein target. Helpful during rapid weight loss for skin and joint support. Choose unflavored hydrolyzed collagen and mix into coffee or smoothies.
Full answer
Don't see your question? Send it in — our clinical team answers within 5 business days.
Was this page helpful?
Excess vs placebo: +10.9 pp
Excess vs placebo: +8.3 pp
Excess vs placebo: +7.6 pp
Excess vs placebo: +4.7 pp
Excess vs placebo: +1.4 pp
Excess vs placebo: +4.1 pp
Excess vs placebo: +4.0 pp
Excess vs placebo: +1.5 pp
Excess vs placebo: +1.0 pp
Excess vs placebo: 0.0 pp
Save ~$11,530.44/yr vs cash list price
Why we picked it: Bundles meds with weekly coaching; Weight Watchers ownership = strong infrastructure.
| $499 |
| $25 |
| $25 |
| 12.5 mg | 4-dose pen | $1086 | $499 | $25 | $25 |
| 15 mg | 4-dose pen | $1086 | $499 | $25 | $25 |
| ConstipationSURMOUNT-1 | 17% | 19% | 15% | 12% | 9% | 7% |
| VomitingSURMOUNT-1 | 13% | 17% | 11% | 7% | 4% | 2% |
| Reflux / heartburnAERS pooled | 8% | 11% | 10% | 8% | 6% | 5% |
| FatigueAERS pooled | 7% | 9% | 7% | 5% | 4% | 3% |
| Hair shedding (telogen)SURMOUNT-1 (5% total) | — | — | 1% | 3% | 5% | 4% |
| Gallbladder eventsSURMOUNT-1 (2.6% total) | — | — | 1% | 1% | 2% | 2% |
Color coding: red ≥20%, amber 10-19%, brand 3-9%, faint <3%. — indicates not tracked at that interval.
Be the first to share what worked — side effects, titration experience, dosing, weight-loss timeline. The form below takes ~2 minutes.
FDA-approved or commonly prescribed off-label for these conditions.
Obesity is a chronic, relapsing disease defined by excess body fat that increases health risk. The medical threshold is BMI ≥30, or ≥27 with a weight-related comorbidity. GLP-1 medications Wegovy and Zepbound are FDA-approved for chronic weight management and produce 14–21% mean weight loss in clinical trials.
Learn about ObesityObstructive sleep apnea (OSA) is a chronic condition in which breathing repeatedly stops and starts during sleep due to airway collapse. In December 2024 the FDA expanded Zepbound's indications to include moderate-to-severe OSA in adults with obesity — the first weight-loss drug approved for the condition.
Learn about Obstructive sleep apneaNon-alcoholic fatty liver disease (NAFLD), now often called metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease in the US. The progressive inflammatory form (MASH, formerly NASH) can lead to cirrhosis. GLP-1 medications show emerging benefit for both weight loss and direct liver effects.
Learn about NAFLD / MASHReason: Previously: demand increase. Resolved Q4 2024.
Last verified May 15, 2026. Source: FDA Drug Shortage Database.
Other drugs in the same class — GIP/GLP-1 dual receptor agonist.